Agios Pharmaceuticals Inc. (AGIO)

42.99
NASDAQ : Health Technology
Prev Close 43.60
Day Low/High 42.32 / 43.67
52 Wk Low/High 38.62 / 85.00
Avg Volume 534.80K
Exchange NASDAQ
Shares Outstanding 58.75M
Market Cap 2.49B
EPS -6.00
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

These 4 Healthcare Charts Are Signaling Buys

These 4 Healthcare Charts Are Signaling Buys

Here's a rundown of four technical setups that are showing solid trading potential.

Agios upgraded at Oppenheimer

Why Celgene Is a Core Biotech Holding

Why Celgene Is a Core Biotech Holding

Celgene's days of stellar growth will continue to stretch far into the future.

Agios Shares Spike on Planned Drug Application

Agios Shares Spike on Planned Drug Application

The drugmaker plans to submit the first targeted-blood-cancer drug to the U.S. by the end of the year.

Agios upgraded at Canaccord

Agios upgraded at JP Morgan

Don't Buy Into This Kind of Bull

Don't Buy Into This Kind of Bull

Risks far outweigh the possible rewards of buying into late bullishness.

Markers Spotted Point to a Top

Markers Spotted Point to a Top

At the very least, move those stop loss levels in very close on long positions.

2 'Rules of the Road' for Biotech Investing

2 'Rules of the Road' for Biotech Investing

Follow these maxims and you should do well in this volatile sector.

Agios downgraded at Leerink

Jim Cramer Says Own Allergan, Disney, MasterCard, Starbucks

Jim Cramer Says Own Allergan, Disney, MasterCard, Starbucks

TheStreet's Jim Cramer answers viewers' questions on Allergan, Pfizer, Disney, MasterCard, Chipotle, Under Armour and more.

Stocks Low But Not Tempting

Picking up some high yielders might be worthwhile.

Agios downgraded at Canaccord

Biotech Stocks at a Crossroad

Own them, or take something off the table?

Here Are the 2 Best CEOs You Can Bank On

And they're both named Bob.

A Tasty Reversal With 6 Key Ingredients

But tomorrow we hear from the banks.

Momentum Is Not Dead

The chasing in certain areas was intense.

GMCR Starts to Look Interesting

I would continue to take any buy triggers in this one.

Go With What's Worked, Part 1

Throughout this historic run, four groups have consistently led the market.

A Study on Apple

Also on Agios Pharmaceuticals

Damage to Indices Was Fairly Minimal

But stay disciplined, honor your stops and protect gains.

It Doesn't Stop

The end-of-the-year phenomenon is working.

You Have to Love Biotech

In this era of turmoil, investors can take comfort in this sector.

Cramer: A Dozen Sectors to Snap Up

As 2014 winds down, you could almost throw darts at these standout groups -- but here are my own picks.

Here's Your Thesis to Buy

This market provides a slew of reasons to buy right now.

Volatility Smokescreen

Bet with common sense not against it.